SI3066097T1 - Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-((1r)-4 -(trifluormetil)-2,3-dihidro-1H-inden-1-il)-1,2,3,4-tetrahidropirimidin- 5-ogljikove kisline - Google Patents

Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-((1r)-4 -(trifluormetil)-2,3-dihidro-1H-inden-1-il)-1,2,3,4-tetrahidropirimidin- 5-ogljikove kisline

Info

Publication number
SI3066097T1
SI3066097T1 SI201430450T SI201430450T SI3066097T1 SI 3066097 T1 SI3066097 T1 SI 3066097T1 SI 201430450 T SI201430450 T SI 201430450T SI 201430450 T SI201430450 T SI 201430450T SI 3066097 T1 SI3066097 T1 SI 3066097T1
Authority
SI
Slovenia
Prior art keywords
dihydro
tetrahydropyrimidin
trifluormethyl
benzoxazol
inden
Prior art date
Application number
SI201430450T
Other languages
English (en)
Slovenian (sl)
Inventor
Britta Olenik
Birgit Keil
Martin-Holger Hinz
Chantal Furstner
Mario Jeske
Jens Ackerstaff
Original Assignee
Bayer Pharma Aktiengeselschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengeselschaft filed Critical Bayer Pharma Aktiengeselschaft
Publication of SI3066097T1 publication Critical patent/SI3066097T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI201430450T 2013-11-08 2014-11-05 Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-((1r)-4 -(trifluormetil)-2,3-dihidro-1H-inden-1-il)-1,2,3,4-tetrahidropirimidin- 5-ogljikove kisline SI3066097T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13192177 2013-11-08
PCT/EP2014/073801 WO2015067652A1 (de) 2013-11-08 2014-11-05 Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure
EP14793565.4A EP3066097B1 (de) 2013-11-08 2014-11-05 Salze von 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure

Publications (1)

Publication Number Publication Date
SI3066097T1 true SI3066097T1 (sl) 2017-12-29

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430450T SI3066097T1 (sl) 2013-11-08 2014-11-05 Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-((1r)-4 -(trifluormetil)-2,3-dihidro-1H-inden-1-il)-1,2,3,4-tetrahidropirimidin- 5-ogljikove kisline

Country Status (32)

Country Link
US (1) US9926305B2 (enExample)
EP (1) EP3066097B1 (enExample)
JP (1) JP6446051B2 (enExample)
KR (1) KR102351418B1 (enExample)
CN (1) CN105658647B (enExample)
AP (1) AP2016009181A0 (enExample)
AU (1) AU2014345599B2 (enExample)
BR (1) BR112016010253A8 (enExample)
CA (1) CA2929780C (enExample)
CL (1) CL2016001096A1 (enExample)
CY (1) CY1119520T1 (enExample)
DK (1) DK3066097T3 (enExample)
EA (1) EA033132B1 (enExample)
ES (1) ES2645480T3 (enExample)
HR (1) HRP20171603T1 (enExample)
HU (1) HUE035021T2 (enExample)
IL (1) IL245407B (enExample)
LT (1) LT3066097T (enExample)
MA (1) MA39020A1 (enExample)
ME (1) ME02907B (enExample)
MX (1) MX366848B (enExample)
MY (1) MY190108A (enExample)
NO (1) NO3066097T3 (enExample)
PH (1) PH12016500853B1 (enExample)
PL (1) PL3066097T3 (enExample)
PT (1) PT3066097T (enExample)
RS (1) RS56509B1 (enExample)
SA (1) SA516371082B1 (enExample)
SI (1) SI3066097T1 (enExample)
TN (1) TN2016000170A1 (enExample)
UA (1) UA117686C2 (enExample)
WO (1) WO2015067652A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) * 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
CN114671856B (zh) * 2020-12-25 2023-10-20 广东东阳光药业股份有限公司 多取代的尿嘧啶衍生物及其用途
US20250302837A1 (en) * 2022-04-05 2025-10-02 Socpra Sciences Santé Et Humaines S.E.C. Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295952A1 (en) * 2000-10-19 2002-04-29 Nippon Kayaku Kabushiki Kaisha Novel remedies or preventives for angiostenosis
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
CN104168779A (zh) * 2012-03-05 2014-11-26 格拉图克技术私人有限公司 膳食补充剂
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
HK1224288A1 (zh) * 2013-11-08 2017-08-18 Bayer Pharma Aktiengesellschaft 作为类糜蛋白酶抑制剂的取代的尿嘧啶

Also Published As

Publication number Publication date
CY1119520T1 (el) 2018-03-07
JP6446051B2 (ja) 2018-12-26
LT3066097T (lt) 2018-02-12
CL2016001096A1 (es) 2016-12-23
MX2016005971A (es) 2016-08-11
HRP20171603T1 (hr) 2017-12-01
PH12016500853B1 (en) 2021-03-24
US20160289220A1 (en) 2016-10-06
DK3066097T3 (da) 2017-11-06
IL245407A0 (en) 2016-06-30
KR20160078980A (ko) 2016-07-05
JP2016535096A (ja) 2016-11-10
MX366848B (es) 2019-07-26
EA201600381A1 (ru) 2016-10-31
RS56509B1 (sr) 2018-02-28
NO3066097T3 (enExample) 2018-01-13
UA117686C2 (uk) 2018-09-10
CN105658647A (zh) 2016-06-08
ME02907B (me) 2018-04-20
NZ719532A (en) 2021-06-25
PT3066097T (pt) 2017-11-10
CA2929780C (en) 2022-03-22
AP2016009181A0 (en) 2016-04-30
PL3066097T3 (pl) 2018-01-31
AU2014345599B2 (en) 2019-02-14
WO2015067652A1 (de) 2015-05-14
CA2929780A1 (en) 2015-05-14
BR112016010253A2 (pt) 2017-08-08
MY190108A (en) 2022-03-29
HUE035021T2 (en) 2018-03-28
HK1222171A1 (zh) 2017-06-23
TN2016000170A1 (en) 2017-10-06
US9926305B2 (en) 2018-03-27
ES2645480T3 (es) 2017-12-05
EP3066097B1 (de) 2017-08-16
IL245407B (en) 2019-10-31
PH12016500853A1 (en) 2016-06-20
MA39020A1 (fr) 2017-04-28
EA033132B1 (ru) 2019-08-30
KR102351418B1 (ko) 2022-01-17
AU2014345599A1 (en) 2016-05-19
SA516371082B1 (ar) 2019-05-16
CN105658647B (zh) 2019-09-06
EP3066097A1 (de) 2016-09-14
BR112016010253A8 (pt) 2021-06-22

Similar Documents

Publication Publication Date Title
IL285971A (en) Pyrimidinedione compounds against cardiac conditions
MA40551A (fr) Composés actifs envers des bromodomaines
SG10201912070VA (en) Toothbrush system with magnetometer for dental hygiene monitoring
MA41272A (fr) 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
EP3698755C0 (en) FILAMENT MANAGEMENT DEVICE
EP2928400A4 (en) ELECTRO-SURGICAL HAND TOOL
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
PT3431035T (pt) Instrumento para brocagem dos canais radiculares
BR112016013502A2 (pt) unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.
HRP20160250T1 (hr) Postupak za pripravu 2-(2,3-dimetilfenil)-1-propanala s kloracetonom
GB201322237D0 (en) Surgical reamer
DK3310333T3 (da) Oralt dispergibel doseringsenhed indeholdende en estetrolkomponent
SG11201703356TA (en) Management of medication preparation with dynamic processing
IL251379B (en) Compositions for oral care containing zinc, arginine and serine
EP3238763A4 (en) Extracorporeal circulation management device and extracorporeal circulation device including same
CL2017001467A1 (es) Compuestos de dihidropirimidin - 2 - ona y sus usos médicos
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
SI3066097T1 (sl) Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-((1r)-4 -(trifluormetil)-2,3-dihidro-1H-inden-1-il)-1,2,3,4-tetrahidropirimidin- 5-ogljikove kisline
HUE055559T2 (hu) Menetes fogászati implantátum
BR112017007509A2 (pt) Processo para a preparação de 1-(3,5-dicloro-4- fluoro-fenil)-2,2,2-trifluoro-etanona
IL254578A0 (en) Abscisic acid (s)-2' vinyl derivatives
IL252447B (en) Oral care composition
GB2529601B (en) Dynamic management of integration protocols
IL256719B (en) Oral care compositions
HUE071186T2 (hu) Trazodon és gabapentin kombinációja fájdalom kezelésére